KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Assets (2016 - 2025)

Historic Assets for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $114.1 billion.

  • Astrazeneca's Assets rose 964.96% to $114.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $114.1 billion, marking a year-over-year increase of 964.96%. This contributed to the annual value of $114.1 billion for FY2025, which is 964.96% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Assets is $114.1 billion, which was up 964.96% from $114.5 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Assets peaked at $114.5 billion during Q3 2025, and registered a low of $104.0 million during Q4 2021.
  • For the 5-year period, Astrazeneca's Assets averaged around $94.3 billion, with its median value being $100.7 billion (2022).
  • Its Assets has fluctuated over the past 5 years, first tumbled by 9979.68% in 2021, then skyrocketed by 9267211.54% in 2022.
  • Over the past 5 years, Astrazeneca's Assets (Quarter) stood at $104.0 million in 2021, then skyrocketed by 92672.12% to $96.5 billion in 2022, then increased by 4.8% to $101.1 billion in 2023, then grew by 2.88% to $104.0 billion in 2024, then grew by 9.65% to $114.1 billion in 2025.
  • Its Assets was $114.1 billion in Q4 2025, compared to $114.5 billion in Q3 2025 and $112.4 billion in Q2 2025.